Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07591779
Starting soon Observational

Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment

NCT07591779 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Limoges
Phase
Observational
Started
2026-06-01
Last updated
2026-05-22

Condition(s) studied

Charcot-Marie-Tooth Disease, Type IAPeripheral Neuropathy HereditaryMotor ActivityWalking, DifficultyNeuromuscular Diseases

Study summary

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.

This research will:

In the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel "Nano-Cur" treatment currently under development.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years 2. Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis) 3. Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and/or having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges 4. Ability to walk independently (with or without walking aids) 5. Informed consent obtained 6. Affiliated to French social security system Exclusion Criteria: 1. Other associated neurological condition that could independently affect walking or motor activity 2. Inability to wear the sensor device (skin allergy, sensory intolerance) 3. Inability to comply with study procedures (cognitive impairment, no fixed domicile) 4. Participation in another interventional study during the same period 5. Pregnant or breastfeeding women 6. Patients under legal protection (guardianship or curatorship)

Primary outcome measure(s)

  • Pearson/Spearman r: daily step count (ActiGraph) vs. CMT-FOM total score — Day 1 (CMT-FOM)
    Correlation coefficient (r : -1 to +1) between mean daily step count (steps/day) over 7 days and CMT-FOM total score obtained at Day 1 hospital visit.
  • Pearson/Spearman r: daily step count (ActiGraph) vs. CMT-FOM total score — Day 7 (home monitoring)
    Correlation coefficient (r : -1 to +1) between mean daily step count (steps/day) over 7 days and CMT-FOM total score obtained at Day 1 hospital visit.
  • Pearson/Spearman r: daily activity counts (ActiGraph) vs. CMT-FOM total score — Day 1
    Correlation coefficient (r : -1 to +1) between mean daily activity counts (raw accelerometry counts/day) over 7 days and CMT-FOM total score.
  • Pearson/Spearman r: daily activity counts (ActiGraph) vs. CMT-FOM total score — Day 7 (home monitoring)
    Correlation coefficient (r : -1 to +1) between mean daily activity counts (raw accelerometry counts/day) over 7 days and CMT-FOM total score.
  • Pearson/Spearman r: daily sedentary time (ActiGraph) vs. CMT-FOM total score — Day 1
    Correlation coefficient (r : -1 to +1) between mean daily sedentary time (minutes/day) over 7 days and CMT-FOM total score.
  • Pearson/Spearman r: daily sedentary time (ActiGraph) vs. CMT-FOM total score — Day 7 (home monitoring)
    Correlation coefficient (r : -1 to +1) between mean daily sedentary time (minutes/day) over 7 days and CMT-FOM total score.
  • Pearson/Spearman r: composite sensor score vs. CMT-FOM sub-scores — Day 1
    Correlation coefficient (r : -1 to +1) between ActiGraph-derived metrics and CMT-FOM sub-domain scores (upper limb, lower limb, balance, endurance). Reported separately per sub-score.
  • Pearson/Spearman r: composite sensor score vs. CMT-FOM sub-scores — Day 7 (home monitoring)
    Correlation coefficients (r : -1 to +1) between ActiGraph-derived metrics and CMT-FOM sub-domain scores (upper limb, lower limb, balance, endurance). Reported separately per sub-score.

Trial sites (1)

FacilityCityRegionStatus
Chu de Limoges Limoges France

More University Hospital, Limoges trials in France

Hemodynamic Impact of the Spontaneous Ventilation Test in Patients at Risk of Weaning Pulmonary Oedema Starting soon
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood. Recruiting
Albumin Modifications as Early Biomarkers of Chronic Liver Diseases Recruiting
Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response Active, not recruiting
Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study Recruiting

Other trials for the same condition

Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System Recruiting
Polygraphy at Home for Neuromuscular Patients Under Non-invasive Mechanical Ventilation Recruiting
Wheelchair Positioning and Neuromuscular Diseases Recruiting
Respiratory Muscles and Work of Breathing in Children Recruiting
Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07591779 on ClinicalTrials.gov ↗ ← All trials in France